Akeso, Inc.
9926.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$100.37B
Close$
Share Statistics
| Market cap | $100.37 Billion |
|---|---|
| Enterprise Value | $96.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.2 |
| Beta | 0.03 |
| Outstanding Shares | 918,644,386 |
Return
| Return on Equity | -21.19% |
|---|---|
| Return on Assets | -11.09% |
| Return on Invested Capital | -14.35% |
Valuation & Multiples
| P/E Ratio | -89.3 |
|---|---|
| PEG | 335.57 |
| Price to Sales | 15.82 |
| Price to Book Ratio | 10.54 |
| Enterprise Value to Revenue | 16.36 |
| Enterprise Value to EBIT | -50.44 |
| Enterprise Value to Net Income | -54 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.74 B
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$3.22 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Akeso, Inc.
4,082 employees
CEO: Yu Xia Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer...